Efficacy and adverse effects of remdesivir in patients with COVID-19 pneumonia: a retrospective study
Open Access
- 30 April 2025
- journal article
- Published by Medip Academy in International Journal Of Community Medicine And Public Health
- Vol. 12 (5) , 2004-2010
Abstract
Background: Remdesivir is an antiviral medication approved by the US FDA to treat COVID-19 in hospitalized patients. However, it has unknown adverse effects and has shown deleterious impacts on several organ systems in randomized controlled trials. This study aims to describe the safety and efficacy of Remdesivir administration in a cohort of 586 patients admitted to a tertiary hospital in Qatar for COVID-19-related reasons. Methods: A retrospective study of 586 patients admitted with a diagnosis of COVID-19 and treated with Remdesivir were compared to 200 patients with COVID-19 who did not receive Remdesivir. Results: The rate of mechanical ventilation admission to the intensive care unit was comparable across the two groups (2.35% vs. 2%, p=0.75). Death rates were similar between the two groups (0.02% vs. 0.03%, p=0.43). There was a mean reduction in heart rate within the first three days of antiviral therapy. Negligible variations in serum AST, ALT, ALP, and eGFR levels were detected. Remdesivir-treated patients had a significantly shorter hospital stay. Conclusions: When using Remdesivir in COVID-19 patients, it's important to be cautious by evaluating baseline parameters and avoiding concurrent use of drugs that could affect the heart, kidneys, or liver.Keywords
All Related Versions
This publication has 22 references indexed in Scilit:
- Quercetin for the treatment of COVID‐19 patients: A systematic review and meta‐analysisReviews in Medical Virology, 2023
- Facial palsy as a manifestation of COVID‐19: A systematic review of casesHealth Science Reports, 2022
- Remdesivir for 5 or 10 Days in Patients with Severe Covid-19New England Journal of Medicine, 2020
- Remdesivir for the Treatment of Covid-19 — Final ReportNew England Journal of Medicine, 2020
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19JAMA, 2020
- Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation statusPharmacological Research, 2020
- Liver injury in remdesivir-treated COVID-19 patientsHepatology International, 2020
- Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID‐19 Pandemic: AASLD Expert Panel Consensus StatementHepatology, 2020
- Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trialThe Lancet, 2020
- Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymeraseAntiviral Research, 2019